HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazilian Blowout maintains product safety

This article was originally published in The Rose Sheet

Executive Summary

Following independent testing conducted Oct. 9 by "one of California's leading environmental safety companies," Brazilian Blowout says formaldehyde exposure levels at an unnamed salon performing Brazilian Blowout straightening treatments were found to be six times lower than the federal Occupational Safety and Health Administration's "most stringent and conservative standard for air quality safety." Health Canada had issued an advisory Oct. 7 urging stylists to stop using Brazilian Blowout products based on consumer complaints and testing that identified formaldehyde concentrations at higher-than-accepted levels (1"The Rose Sheet" Oct. 11, 2010, In Brief). In an Oct. 11 release, Brazilian Blowout distributor Cavideu USA suggests discrepancy between test results highlights need for updated testing standards. "Industry experts have for years expressed concerns that standardized government testing methods for formaldehyde in water-based cosmetic products are inaccurate and do not measure the actual formaldehyde levels.

You may also be interested in...



Formaldehyde found in Brazilian Blowout products

After receiving complaints from consumers, Oregon's Occupational Safety & Health Division and Canadian regulatory body Health Canada tested and determined products from California-based Brazilian Blowout contain high levels of formaldehyde. Using four different testing methods, Oregon OSHA found product samples to have formaldehyde levels between 4.85% and 10.6%, while Health Canada found samples with 12% formaldehyde. In its Oct. 5 release, Brazilian Blowout - marketer of a hair-smoothing treatment administered by salons - says its own testing shows trace formaldehyde levels of less than 0.002%, which is considered safe and "allows for use of the term 'formaldehyde-free.'" Health Canada received complaints of "burning eyes, nose and throat, breathing difficulties," it says, as well as one report of hair loss from use of Brazilian Blowout products. It issued an advisory Oct. 7 urging stylists to stop using Brazilian Blowout treatments and directing consumers to seek medical attention if they are exhibiting reactions. Brazilian Blowout maintains the level of formaldehyde is 10,000 times less than the 40 parts-per-million concentration limit set by California's Proposition 65. As the firm continues its investigation into the claims, "we are confident that all misinformation and inaccurate data will soon be dispelled," it says. FDA weighs in with a notice on its website Oct. 8, stating it has not received any official adverse event reports on Brazilian Blowout but is working with state and local organizations "to determine whether the products or ingredients would be likely to cause health problems under the intended conditions of use.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel